
|Articles|October 15, 2003
Glaucoma experts translate messages from NEI clinical trials
Chicago-In the late 1980s, ophthalmologists were challenged by Eddy and Billings to prove that IOP was an essential element in the management of primary open-angle glaucoma (POAG). Recent results from a number of National Eye Institute (NEI)-sponsored randomized controlled trials confirm that IOP reduction is effective in slowing both disease development and its progression. The results of those studies, however, have raised new issues in glaucoma management.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5